Fact checked by Nick Blackmer The Food and Drug Administration (FDA) on Thursday approved Journavx (suzetrigine), a new non-opioid painkiller that promises to be nonaddictive. Journavx is approved to ...

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

A legacy bipartisan initiative to combat HIV and AIDS in Africa is collateral damage from President Donald Trump’s directive to halt all U.S. foreign assistance, despite efforts to exempt ...